ConductScience.org, home

Paper38575868

CGRP-targeted medication in chronic migraine - systematic review.

Oliveira R and 2 others. J Headache Pain, 2024. Cited by 60 papers, by iCite.

Cite this record

ConductScience Library. CGRP-targeted medication in chronic migraine - systematic review. Papers, record 38575868. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38575868

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
CGRP-targeted medication in chronic migraine - systematic review.
PubMed
Journal
J Headache Pain
PubMed
Year
2024
PubMed
Publication types
Journal Article, Systematic Review
PubMed
Citations, by iCite
60
iCite
Relative citation ratio, by iCite
13.15, provisional
iCite
Revised in PubMed
2026-04-14
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Oliveira RRenato
2Gil-Gouveia RRaquel
3Puledda FFrancescahttps://orcid.org/0000-0002-1933-4049

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Calcitonin Gene-Related PeptideMajor topic
Migraine DisordersMajor topic
Humans
Antibodies, Monoclonal
Receptors, Calcitonin Gene-Related Peptide
Calcitonin Gene-Related Peptide Receptor Antagonists

References56

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135690723European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update.J Headache Pain2022https://conductscience.org/library/papers/35690723PubMed
227389092Chronic migraine: risk factors, mechanisms and treatment.Nat Rev Neurol2016https://conductscience.org/library/papers/27389092PubMed
335146696Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.CNS Drugs2022https://conductscience.org/library/papers/35146696PubMed
430446596Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study.Neurology2018https://conductscience.org/library/papers/30446596PubMed
522300068Adherence with migraine prophylaxis in clinical practice.Pain Pract2012https://conductscience.org/library/papers/22300068PubMed
632517693Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience.J Headache Pain2020https://conductscience.org/library/papers/32517693PubMed
735383922Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid.Headache2022https://conductscience.org/library/papers/35383922PubMed
834409517Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case series.Neurol Sci2021https://conductscience.org/library/papers/34409517PubMed
931563224Migraine: Epidemiology, Burden, and Comorbidity.Neurol Clin2019https://conductscience.org/library/papers/31563224PubMed
1037072224Late Response to Anti-CGRP Monoclonal Antibodies in Migraine: A Multicenter Prospective Observational Study.Neurology2023https://conductscience.org/library/papers/37072224PubMed
1133615840CGRP monoclonal antibody prevents the loss of diffuse noxious inhibitory controls (DNIC) in a mouse model of post-traumatic headache.Cephalalgia2021https://conductscience.org/library/papers/33615840PubMed
1234644203Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study.Cephalalgia2022https://conductscience.org/library/papers/34644203PubMed
1332546227European headache federation consensus on the definition of resistant and refractory migraine : Developed with the endorsement of the European Migraine & Headache Alliance (EMHA).J Headache Pain2020https://conductscience.org/library/papers/32546227PubMed
1436548744OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine.Toxins (Basel)2022https://conductscience.org/library/papers/36548744PubMed
1532602955Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review.Headache2020https://conductscience.org/library/papers/32602955PubMed
1627206958Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents.Cephalalgia2017https://conductscience.org/library/papers/27206958PubMed
1732122324
Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study.
J Headache Pain2020https://conductscience.org/library/papers/32122324PubMed
1832810212Differential medication overuse risk of novel anti-migraine therapeutics.Brain2020https://conductscience.org/library/papers/32810212PubMed
1934873540Quality of Life and Disability Among Migraine Patients: A Single-Center Study in AlAhsa, Saudi Arabia.Cureus2021https://conductscience.org/library/papers/34873540PubMed
2033880725Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review.Pain Ther2021https://conductscience.org/library/papers/33880725PubMed

See all 56 referencesDownload CSV of references

Cited by53

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 60 citations.

PMIDTitleJournalYearIn PapersSource
42980719Real-World Effectiveness and Utilisation of Anti-CGRP Monoclonal Antibodies for Migraine Prevention in a Public Healthcare System.Drugs Real World Outcomes2026https://conductscience.org/library/papers/42980719PubMed
42941670Middle Meningeal Artery Embolization Using Non-Adhesive Liquid Embolic Agents for Chronic Resistant Migraine: Interim Feasibility and Safety Analysis of a Prospective Single-Arm Trial.J Clin Med2026https://conductscience.org/library/papers/42941670PubMed
42939289Triptans and Lasmiditan Are Safe and Effective in Patients with Migraine Attacks Associated with Neurodevelopmental Disorders: A Single-Center Prospective Clinical Case Series.Brain Sci2026https://conductscience.org/library/papers/42939289PubMed
42922561Low-Dose Interleukin-2 Resolves Stress-Induced Chronic Sensitization Independent of Opioid Receptor Signaling.bioRxiv2026https://conductscience.org/library/papers/42922561PubMed
42902147Targeting neuronal FKBP5 attenuates mechanical allodynia by suppressing NF-κB-mediated neuroinflammation in an NTG-induced chronic migraine mouse model.J Headache Pain2026https://conductscience.org/library/papers/42902147PubMed
42853529Migraine and Obesity: From Shared Mechanisms to Therapeutic Strategies.Neurol Ther2026https://conductscience.org/library/papers/42853529PubMed
42814345Persistence and Reasons for Treatment Discontinuation of Anti-CGRP Therapies in Migraine Prophylaxis: A Systematic Review and Meta-analysis of Real-World Studies.Pain Ther2026https://conductscience.org/library/papers/42814345PubMed
42741009
A multidisciplinary multicentric approach to the identification of predictive biomarkers of response to erenumab - the protocol of the phase 4, European, open-label controlled trial of the BIOMIGA project.
Front Neurol2026https://conductscience.org/library/papers/42741009PubMed
42662157OnabotulinumtoxinA for chronic migraine: A real-life multicenter study of 479 patients.Ther Adv Neurol Disord2026https://conductscience.org/library/papers/42662157PubMed
42548107Global, regional, and national burden of migraine in postmenopausal women: a 32-year analysis from the global burden of disease study 1990-2021.J Oral Facial Pain Headache2026https://conductscience.org/library/papers/42548107PubMed
42469638From tooth pain to trigeminal sensitization: translational models, experimental readouts, and mechanism-guided therapeutic opportunities in odontogenic and headache-related orofacial pain.J Headache Pain2026https://conductscience.org/library/papers/42469638PubMed
42399797Predictive factors of response to anti-CGRP pathway drugs in people with multiple sclerosis.J Headache Pain2026https://conductscience.org/library/papers/42399797PubMed
42349425A highly efficient method to differentiate CGRP-expressing peptidergic nociceptors from human induced pluripotent stem cells.Stem Cell Reports2026https://conductscience.org/library/papers/42349425PubMed
42238828Efficacy of Erenumab in Patients With Treatment-Resistant Chronic Migraine and Medication Overuse Headache.Neurosciences (Riyadh)2026https://conductscience.org/library/papers/42238828PubMed
42220284An exploration of possible future non-pharmacological multidisciplinary treatments to potentiate withdrawal strategy and recovery from medication overuse headache (MOH): a narrative review.J Oral Facial Pain Headache2026https://conductscience.org/library/papers/42220284PubMed
42201619CGRP-targeted therapies for migraine and the risk of infection.Intern Emerg Med2026https://conductscience.org/library/papers/42201619PubMed
42168858Functional characterisation of dura mater αCGRP degradation fragments at vascular, immune, and CGRP receptor targets.J Headache Pain2026https://conductscience.org/library/papers/42168858PubMed
42147339Efficacy and safety of Chinese botanical drug decoctions for migraine: a Bayesian network meta-analysis.Front Pharmacol2026https://conductscience.org/library/papers/42147339PubMed
42032384Use of CGRP Monoclonal Antibodies in Japan, South Korea, and Taiwan: A Narrative Review.Curr Pain Headache Rep2026https://conductscience.org/library/papers/42032384PubMed
41987050Trends in migraine-specific medication consumption: a multinational analysis of 73 countries based on IQVIA-MIDAS database, 2015 to 2024.J Headache Pain2026https://conductscience.org/library/papers/41987050PubMed

See all 53 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CALCA796PubTator's text mininghttps://conductscience.org/library/genes/796

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38575868

GET https://conductscience.org/api/papers/v1/38575868/references?page=2